Capricor's DMD cell therapy BLA gets three-month FDA extension
Capricor Therapeutics has received a three-month extension to the FDA's target action date for its Biologics Licence Application (BLA) for Deramiocel, an allogeneic cell therapy in development for Duchenne muscular dystrophy (DMD). The new PDUFA date is 22 November 2026, moved from the original 22 August deadline.
The extension follows Capricor's submission of a BLA amendment that adds 24-month open-label extension data from the pivotal Phase 3 HOPE-3 study, alongside additional robustness analyses. The company said the amendment also includes a request to refine the proposed indication to focus specifically on upper limb function, which was HOPE-3's primary endpoint. The FDA's Centre for Biologics Evaluation and Research accepted the amendment, citing significant unmet medical need in DMD, and classified it as a major amendment, triggering the standard three-month clock extension.
Trial context and clinical rationale
HOPE-3 met its primary endpoint, showing a statistically significant benefit in upper limb function over the study period. Chief executive Linda Marbán said the additional year of follow-up data now gives Capricor one of the most extensive datasets evaluating upper limb function in DMD patients. The refined indication request represents a narrowing of scope compared with the original BLA, a regulatory strategy that can sometimes smooth the path to approval by aligning the label more precisely with the trial evidence.
Deramiocel is composed of allogeneic cardiosphere-derived cells, which are reported in preclinical and clinical work to exert immunomodulatory and anti-fibrotic effects via exosome secretion. The mechanism targets macrophage phenotype, shifting cells from pro-inflammatory to a tissue-repair profile. The product holds Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US, the last of which could entitle Capricor to a Priority Review Voucher on approval, a commercially valuable instrument that can be sold or transferred to other sponsors.
Regulatory and competitive landscape
A July 2026 Advisory Committee meeting preceded this amendment, suggesting the agency had questions that Capricor is now addressing with the longer-term dataset. Advisory Committee votes are not binding, but a mixed or negative panel outcome typically prompts sponsors to sharpen the clinical narrative before the formal PDUFA decision, which appears consistent with Capricor's approach here.
DMD remains an area of intense regulatory scrutiny and commercial interest. Sarepta Therapeutics holds several approved or conditionally approved DMD therapies in the US, including its gene therapy Elevidys, and the agency has previously drawn criticism for its handling of accelerated approvals in the indication. The FDA's willingness to accept Capricor's amendment and extend review rather than issue a Complete Response Letter at the original date is a constructive signal, though it does not guarantee approval. Investors should note that the litigation with Nippon Shinyaku over distribution rights, referenced in Capricor's standard forward-looking statement boilerplate, remains a potential commercial overhang regardless of the regulatory outcome.
The November decision window will be a significant near-term catalyst for the San Diego-based company, which is also advancing its StealthX exosome delivery platform across other disease areas.